Androgen-Deprivation Therapy KOL Commentaries - Androgen-Deprivation Therapy KOL Commentary Primary and novel androgen deprivation therapy for prostate cancer: balancing efficacy and potential toxicitiesMary-Ellen Taplin VIEW MORE Case study Case Study (2019-2023): Changing treatmentsMary-Ellen Taplin VIEW MORE Case study mHSPC: A Clinical Case StudyJordan Ciuro & Atish Choudhury VIEW MORE KOL Commentary Updates in mHSPC ASCO Genitourinary Symposium 2023Atish Choudhury & Jordan Ciuro VIEW MORE Case study Patient Case StudyWilliam Oh VIEW MORE Infographics - Androgen-Deprivation Therapy Biomarkers for the Prediction of Disease Progression, Prognosis, and Treatment Response of Metastatic Prostate Cancer VIEW INFOGRAPHIC Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer VIEW INFOGRAPHIC Intensifying Metastatic Hormone-Sensitive Prostate Cancer Treatment VIEW INFOGRAPHIC Articles - Androgen-Deprivation Therapy Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial READ MORE Treatment options for metastatic hormone-sensitive prostate cancer READ MORE The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups READ MORE Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy READ MORE Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice READ MORE Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins READ MORE Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer READ MORE Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design READ MORE Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer READ MORE Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer READ MORE Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk READ MORE Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer READ MORE Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis READ MORE Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study READ MORE Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer–specific mortality READ MORE Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial READ MORE Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial READ MORE Facebook Twitter Linkedin
